Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Two-Part, Two-Period, Fixed Sequence Crossover I Study to Evaluate the Effect of CYP3A and P- Glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampicin on the Pharmacokinetics of HMPL-453 Tartrate Tablets in Healthy Subjects

NCT07697157 is registered in ClinicalTrials.gov with Hutchmed as lead sponsor.

NCT NCT07697157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07697157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Two-Part, Two-Period, Fixed Sequence Crossover I Study to Evaluate the Effect of CYP3A and P- Glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampicin on the Pharmacokinetics of HMPL-453 Tartrate Tablets in Healthy Subjects
Lead sponsor
Hutchmed
Phase
Phase 1
Overall status
Completed
Start date
March 1, 2025
Completion date
December 31, 2025
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

health, subjective